

# Gary Remington

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2123647/gary-remington-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218 papers	10,773 citations	50 h-index	98 g-index
225 ext. papers	12,365 ext. citations	5 avg, IF	6.34 L-index

#	Paper	IF	Citations
218	The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans.. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 57, 39-49	1.2	0
217	Childhood trauma exposure and personality traits in schizophrenia patients.. <i>Schizophrenia Research</i> , <b>2022</b> , 241, 221-227	3.6	0
216	Distinct profiles of psychological and neuropsychological functions underlying goal-directed pursuit in schizophrenia.. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2022</b> , 48674221077031	2.6	
215	Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia.. <i>NPJ Schizophrenia</i> , <b>2022</b> , 8, 2	5.5	1
214	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2022</b> , 12, 204512532210965	4.9	1
213	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. <i>NeuroImage: Clinical</i> , <b>2021</b> , 32, 102852	5.3	0
212	Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 136, 468-473	5.2	0
211	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. <i>NPJ Schizophrenia</i> , <b>2021</b> , 7, 22	5.5	7
210	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin Open</i> , <b>2021</b> , 2, sgab006	2.2	7
209	Schizophrenia: Antipsychotics and drug development. <i>Behavioural Brain Research</i> , <b>2021</b> , 414, 113507	3.4	0
208	Adiposity in schizophrenia: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 144, 524-536	6.5	5
207	Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications. <i>Schizophrenia Research</i> , <b>2021</b> , 237, 202-207	3.6	0
206	Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. <i>Schizophrenia Research: Cognition</i> , <b>2021</b> , 26, 100205	2.8	1
205	Trait Anhedonia in Schizophrenia: A Systematic Review and Comparative Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	1
204	Clozapine and COVID-19. <i>Journal of Psychiatry and Neuroscience</i> , <b>2020</b> , 45, E1	4.5	3
203	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 1439-1458	1.3	12
202	Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Journal of Psychopharmacology</i> , <b>2020</b> , 34, 914-919	4.6	0

201	Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , <b>2020</b> , 34, 579-598	6.7	25
200	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 124, 151-158	5.2	12
199	Adherence to clozapine vs. other antipsychotics in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2020</b> , 142, 87-95	6.5	9
198	You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication. <i>Schizophrenia Research</i> , <b>2020</b> , 225, 39-46	3.6	5
197	Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia. <i>Psychiatry Research</i> , <b>2020</b> , 284, 112683	9.9	3
196	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 632-640	8.7	19
195	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 99, 109839	5.5	4
194	What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. <i>Neuropharmacology</i> , <b>2020</b> , 163, 107591	5.5	14
193	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 11-22	5.1	11
192	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 420-429	3.6	16
191	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 94, 109659	5.5	6
190	Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. <i>Psychiatry Research</i> , <b>2019</b> , 274, 409-413	9.9	1
189	Treatment Recommendations for Tardive Dyskinesia. <i>Canadian Journal of Psychiatry</i> , <b>2019</b> , 64, 388-399	4.8	29
188	Antipsychotics and glucose metabolism: how brain and body collide. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2019</b> , 316, E1-E15	6	27
187	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. <i>European Psychiatry</i> , <b>2019</b> , 61, 63-71	6	6
186	Clozapine-Related Myocarditis and Rechallenge: A Case Series and Clinical Review. <i>Journal of Clinical Psychopharmacology</i> , <b>2019</b> , 39, 380-385	1.7	5
185	A meta-analysis of transcranial direct current stimulation for schizophrenia: "Is more better?". <i>Journal of Psychiatric Research</i> , <b>2019</b> , 110, 117-126	5.2	23
184	Reward-driven decision-making impairments in schizophrenia. <i>Schizophrenia Research</i> , <b>2019</b> , 206, 277-283	3.6	13

183	Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. <i>Schizophrenia Research</i> , <b>2019</b> , 206, 400-406	3.6	5
182	Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1036-1042	8.7	66
181	Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing sitting time among individuals with schizophrenia. <i>Psychiatry Research</i> , <b>2019</b> , 271, 311-318	9.9	6
180	Clozapine-induced myocarditis in Canada: Evidence from spontaneous reports. <i>Schizophrenia Research</i> , <b>2019</b> , 206, 462-463	3.6	2
179	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry</i> , <b>2019</b> , 85, 596-605	7.9	53
178	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , <b>2019</b> , 20, 91-95	3.8	8
177	The Assessment and Treatment of Antipsychotic-Induced Akathisia. <i>Canadian Journal of Psychiatry</i> , <b>2018</b> , 63, 719-729	4.8	32
176	Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. <i>Neuropsychopharmacology</i> , <b>2018</b> , 43, 1700-1705	8.7	13
175	Genetics of tardive dyskinesia: Promising leads and ways forward. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 389, 28-34	3.2	29
174	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. <i>Psychiatry Research - Neuroimaging</i> , <b>2018</b> , 273, 16-24	2.9	10
173	Reduced insulin sensitivity may be related to less striatal glutamate: An H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 285-296	1.2	3
172	Improving outcomes in schizophrenia by preventing early relapses. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 384-386	3.3	6
171	Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of H-MRS studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2018</b> , 86, 340-352	5.5	37
170	Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. <i>Schizophrenia Research</i> , <b>2018</b> , 194, 55-61	3.6	11
169	A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. <i>Schizophrenia Research</i> , <b>2018</b> , 194, 47-54	3.6	7
168	The neural correlates of apathy in schizophrenia: An exploratory investigation. <i>Neuropsychologia</i> , <b>2018</b> , 118, 34-39	3.2	7
167	Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 122-129	3.6	1
166	Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , <b>2018</b> , 193, 29-36	3.6	12

165	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , <b>2018</b> , 268, 114-122	9.9	34
164	Use of Placebo in Clinical Trials of Psychotropic Medication. <i>Canadian Journal of Psychiatry</i> , <b>2018</b> , 63, 338-341	4.8	3
163	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , <b>2018</b> , 686, 17-22	3.3	6
162	Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. <i>Experimental Eye Research</i> , <b>2018</b> , 175, 32-41	3.7	9
161	Investigating the predictors of happiness, life satisfaction and success in schizophrenia. <i>Comprehensive Psychiatry</i> , <b>2018</b> , 81, 42-47	7.3	13
160	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , <b>2018</b> , 33, 523-530	3.9	6
159	Objective investigation of activity preference in schizophrenia: A pilot study. <i>Psychiatry Research</i> , <b>2018</b> , 267, 551-559	9.9	0
158	Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia. <i>Microbial Biotechnology</i> , <b>2017</b> , 11, 229-236	3.3	8
157	Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Schizophrenia Research</i> , <b>2017</b> , 189, 4-8	3.6	8
156	Factors associated with drug attitude in patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , <b>2017</b> , 188, 185-186	3.6	2
155	GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood trauma. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 663-671	2.6	8
154	Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. <i>Psychiatry Research</i> , <b>2017</b> , 254, 112-117	9.9	24
153	Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 2259-2271	8.7	15
152	One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. <i>British Journal of Psychiatry</i> , <b>2017</b> , 211, 137-143	5.4	25
151	Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 78, 140-148	5.5	24
150	Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. <i>Psychoneuroendocrinology</i> , <b>2017</b> , 81, 80-87	5	5
149	Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 764-777	1.3	110
148	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 216-229	11.9	408

147	Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 862-871	1.3	15
146	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , <b>2017</b> , 2, 185-197	4.9	10
145	Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. <i>Canadian Journal of Psychiatry</i> , <b>2017</b> , 62, 656-661	4.8	32
144	Guidelines for the Pharmacotherapy of Schizophrenia in Adults. <i>Canadian Journal of Psychiatry</i> , <b>2017</b> , 62, 604-616	4.8	130
143	Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 312-319	4.6	9
142	Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 72, 23-29	5.5	8
141	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [F]FEPPA. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 118-124	11.9	81
140	72. Behavioral and Neurobiological Correlates of Attention in Schizophrenia in a Virtual Environment. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, S42-S42	1.3	1
139	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 293-301	1.3	38
138	Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 223-228	4.6	6
137	Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings. <i>Psychiatry Research</i> , <b>2016</b> , 244, 415-9	9.9	12
136	Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. <i>Schizophrenia Research</i> , <b>2016</b> , 176, 411-416	3.6	11
135	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. <i>Focus (American Psychiatric Publishing)</i> , <b>2016</b> , 14, 396-402	1.1	2
134	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 121-34	2.3	15
133	Life satisfaction and happiness among young adults with schizophrenia. <i>Psychiatry Research</i> , <b>2016</b> , 242, 174-179	9.9	30
132	A preliminary examination of the validity and reliability of a new Brief Rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). <i>Journal of Psychiatric Research</i> , <b>2016</b> , 80, 87-92	5.2	8
131	Treating Negative Symptoms in Schizophrenia: an Update. <i>Current Treatment Options in Psychiatry</i> , <b>2016</b> , 3, 133-150	3.1	100
130	Characterizing the affective responses to an acute bout of moderate-intensity exercise among outpatients with schizophrenia. <i>Psychiatry Research</i> , <b>2016</b> , 237, 264-70	9.9	2

129	Clozapine administration in clinical practice: once-daily versus divided dosing. <i>Acta Psychiatrica Scandinavica</i> , <b>2016</b> , 134, 234-40	6.5	9
128	Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. <i>Comprehensive Psychiatry</i> , <b>2016</b> , 66, 31-8	7.3	12
127	What symptom domains are associated with patient distress in schizophrenia?. <i>Schizophrenia Research</i> , <b>2016</b> , 176, 329-330	3.6	4
126	Clozapine@ critical role in treatment resistant schizophrenia: ensuring both safety and use. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1193-203	4.1	44
125	Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study. <i>Journal of Neural Transmission</i> , <b>2016</b> , 123, 329-38	4.3	6
124	Consistency between clinician and patient ratings of clozapine-induced side effects. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 200-201	3.6	2
123	Antipsychotics and amotivation. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1539-48	8.7	34
122	Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 168, 483-90	3.6	34
121	Motivated to do well: an examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 166, 276-82	3.6	45
120	Measuring the effects of treatment with antipsychotics. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 514-5	14.5	
119	Insight and subjective measures of quality of life in chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , <b>2015</b> , 2, 127-132	2.8	33
118	Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 407-21	3.7	10
117	Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylozapine. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 579-85	11.9	51
116	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 164, 164-75 <sup>3.6</sup>		53
115	Challenging the need for sustained blockade of dopamine D <sub>2</sub> receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. <i>Schizophrenia Research</i> , <b>2015</b> , 164, 149-54	3.6	9
114	Behavioral effects of food-derived opioid-like peptides in rodents: Implications for schizophrenia?. <i>Pharmacology Biochemistry and Behavior</i> , <b>2015</b> , 134, 70-8	3.9	19
113	Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 446-55	14.5	56
112	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. <i>Medical Hypotheses</i> , <b>2015</b> , 85, 391-6 <sup>3.8</sup>		9



111	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 166, 304-9	3.6	18
110	Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2187-96	1.2	14
109	Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. <i>Canadian Journal of Psychiatry</i> , <b>2015</b> , 60, 215-22	4.8	46
108	Values in First-Episode Schizophrenia. <i>Canadian Journal of Psychiatry</i> , <b>2015</b> , 60, 507-14	4.8	6
107	Schizophrenia and the influence of male gender. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 578-86	1	6
106	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. <i>Canadian Journal of Psychiatry</i> , <b>2015</b> , 60, 515-22	4.8	27
105	The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 510-6	1.7	29
104	Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. <i>Schizophrenia Research</i> , <b>2015</b> , 166, 9-16	3.6	91
103	Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. <i>International Journal of Neuropsychopharmacology</i> , <b>2015</b> , 18, pyv014	5.8	42
102	Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 69-75	3.6	9
101	Distress related to subclinical negative symptoms in a non-clinical sample: Role of dysfunctional attitudes. <i>Psychiatry Research</i> , <b>2015</b> , 230, 249-54	9.9	13
100	Measuring motivation in people with schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 423-426	3.6	15
99	Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 116-26	4.6	36
98	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 161, 351-6	3.6	22
97	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , <b>2015</b> , 161, 429-33	3.6	21
96	Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 295-302	1.2	3
95	What does schizophrenia teach us about antipsychotics?. <i>Canadian Journal of Psychiatry</i> , <b>2015</b> , 60, S14-8	4.8	4
94	Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 693-709	1.2	124



93	Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 52, 50-6	5.2	22
92	Glutamate-mediated excitotoxicity in schizophrenia: a review. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1591-605	1.2	89
91	Use of candidate gene markers to guide antipsychotic dosage adjustment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2014</b> , 54, 315-20	5.5	5
90	Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. <i>Psychopharmacology</i> , <b>2014</b> , 231, 2237-49	4.7	25
89	Relationship between clinical improvement and functional gains with clozapine in schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1622-9	1.2	5
88	Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. <i>Schizophrenia Research</i> , <b>2014</b> , 153, 184-8	3.6	22
87	Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 48, 102-10	5.2	158
86	Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1078-85	1.2	18
85	Impact of primary negative symptoms on functional outcomes in schizophrenia. <i>European Psychiatry</i> , <b>2014</b> , 29, 449-55	6	120
84	Daily activity patterns in remitted first-episode schizophrenia. <i>Comprehensive Psychiatry</i> , <b>2014</b> , 55, 1182-7	7.3	7
83	Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. <i>Schizophrenia Research</i> , <b>2014</b> , 154, 89-92	3.6	12
82	Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 448-58	1.2	18
81	Mean platelet volume in schizophrenia unaltered after 1year of clozapine exposure. <i>Schizophrenia Research</i> , <b>2014</b> , 157, 134-6	3.6	10
80	Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study. <i>Schizophrenia Research</i> , <b>2014</b> , 152, 317-8	3.6	14
79	Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 2769-76	8.7	30
78	Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. <i>Journal of Psychiatry and Neuroscience</i> , <b>2014</b> , 39, E1-2	4.5	2
77	Development and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia. <i>Frontiers in Psychiatry</i> , <b>2014</b> , 5, 68	5	18
76	Antipsychotic dosing: found in translation. <i>Journal of Psychiatry and Neuroscience</i> , <b>2014</b> , 39, 223-31	4.5	12

75	Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 373-83	4	5
74	Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivity. <i>Schizophrenia Research</i> , <b>2014</b> , 160, 43-50	3.6	49
73	Examining strategies to improve accelerometer compliance for individuals living with schizophrenia. <i>Psychiatric Rehabilitation Journal</i> , <b>2014</b> , 37, 333-5	2.4	7
72	Motivational deficits and cognitive test performance in schizophrenia. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 1058-65	4.5	98
71	The neurobiology of relapse in schizophrenia. <i>Schizophrenia Research</i> , <b>2014</b> , 152, 381-90	3.6	25
70	A comparison of cardio-metabolic risk between the deficit and non-deficit subtypes of schizophrenia. <i>Schizophrenia Research</i> , <b>2014</b> , 153, 246-7	3.6	0
69	Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, 506-11	4.6	12
68	Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?. <i>Psychopharmacology</i> , <b>2013</b> , 225, 505-18	4.7	63
67	Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 1017-22	1.2	34
66	Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. <i>Schizophrenia Research</i> , <b>2013</b> , 151, 203-8	3.6	31
65	Risk of neutropenia in a clozapine-treated elderly population. <i>Schizophrenia Research</i> , <b>2013</b> , 148, 183-5	3.6	9
64	Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 881-94	5.9	11
63	Clozapine® role in the treatment of first-episode schizophrenia. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 146-51	11.9	52
62	Examining levels of antipsychotic adherence to better understand nonadherence. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 261-3	1.7	18
61	Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. <i>Psychiatry Research</i> , <b>2012</b> , 197, 1-6	9.9	124
60	Increased stress-induced dopamine release in psychosis. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 561-7	7.9	192
59	Antipsychotics, dopamine D <sub>2</sub> receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. <i>Schizophrenia Research</i> , <b>2012</b> , 140, 214-20	3.6	38
58	Happiness in first-episode schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 141, 98-103	3.6	36

57	Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 95-9	1.7	15
56	Methamphetamine use and schizophrenia: a population-based cohort study in California. <i>American Journal of Psychiatry</i> , <b>2012</b> , 169, 389-96	11.9	86
55	Management of schizophrenia in late life with antipsychotic medications: a qualitative review. <i>Drugs and Aging</i> , <b>2011</b> , 28, 961-80	4.7	19
54	Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. <i>British Journal of Psychiatry</i> , <b>2011</b> , 199, 275-80	5.4	32
53	Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. <i>Pharmacology Biochemistry and Behavior</i> , <b>2011</b> , 100, 86-9	3.9	11
52	Genetics of antipsychotic-induced side effects and agranulocytosis. <i>Current Psychiatry Reports</i> , <b>2011</b> , 13, 156-65	9.1	48
51	An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1439-44	4.6	146
50	"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1042-8	4.6	47
49	Negative symptoms in schizophrenia: avolition and Occam's razor. <i>Schizophrenia Bulletin</i> , <b>2010</b> , 36, 359-69	6.3	419
48	Progress in defining optimal treatment outcome in schizophrenia. <i>CNS Drugs</i> , <b>2010</b> , 24, 9-20	6.7	51
47	Augmenting Clozapine Response in Treatment-Resistant Schizophrenia. <i>Advances in Biological Psychiatry</i> , <b>2010</b> , 129-151		4
46	Clozapine and global cognition in schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 431-6	1.7	26
45	Where to position clozapine: re-examining the evidence. <i>Canadian Journal of Psychiatry</i> , <b>2010</b> , 55, 677-84	4.8	44
44	Antipsychotic dosing: how much but also how often?. <i>Schizophrenia Bulletin</i> , <b>2010</b> , 36, 900-3	1.3	50
43	Motivational deficits as the central link to functioning in schizophrenia: a pilot study. <i>Schizophrenia Research</i> , <b>2009</b> , 115, 333-7	3.6	84
42	Alterations of dopamine and serotonin transmission in schizophrenia. <i>Progress in Brain Research</i> , <b>2008</b> , 172, 117-40	2.9	61
41	Emerging drugs for schizophrenia. <i>Expert Opinion on Emerging Drugs</i> , <b>2008</b> , 13, 479-95	3.7	38
40	The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. <i>Schizophrenia Research</i> , <b>2007</b> , 90, 229-37	3.6	113

39	Tardive dyskinesia: eliminated, forgotten, or overshadowed?. <i>Current Opinion in Psychiatry</i> , <b>2007</b> , 20, 131-7	4.9	52
38	Early use of clozapine for poorly responding first-episode psychosis. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 369-73	1.7	66
37	Augmentation strategies in clozapine-resistant schizophrenia. <i>CNS Drugs</i> , <b>2005</b> , 19, 843-72	6.7	69
36	The crossover approach to switching antipsychotics: what is the evidence?. <i>Schizophrenia Research</i> , <b>2005</b> , 76, 267-72	3.6	34
35	Rational pharmacotherapy in early psychosis. <i>British Journal of Psychiatry</i> , <b>2005</b> , 48, s77-84	5.4	18
34	"Extended" antipsychotic dosing: rationale and pilot data. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 611-3	1.7	24
33	Predictors and markers of clozapine response. <i>Psychopharmacology</i> , <b>2005</b> , 179, 317-35	4.7	30
32	Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1620-5	11.9	118
31	Switching atypical antipsychotics: a review. <i>Acta Neuropsychiatrica</i> , <b>2004</b> , 16, 301-13	3.9	11
30	The use of pharmacotherapy in the prodrome of schizophrenia. <i>CNS Spectrums</i> , <b>2004</b> , 9, 579-86	1.8	6
29	Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. <i>Canadian Journal of Psychiatry</i> , <b>2004</b> , 49, 753-60	4.8	204
28	Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. <i>Neuropsychopharmacology</i> , <b>2003</b> , 28, 1433-9	8.7	48
27	The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. <i>Psychopharmacology</i> , <b>2003</b> , 165, 166-71	4.7	51
26	Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. <i>Journal of Psychiatry and Neuroscience</i> , <b>2003</b> , 28, 275-84	4.5	57
25	The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2002</b> , 26, 361-80	9	64
24	Atypical antipsychotics: where does ziprasidone fit?. <i>Expert Review of Neurotherapeutics</i> , <b>2002</b> , 2, 13-24	4.3	
23	Significant dissociation of brain and plasma kinetics with antipsychotics. <i>Molecular Psychiatry</i> , <b>2002</b> , 7, 317-21	15.1	144
22	A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1305-13	11.9	130

21	Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. <i>Biological Psychiatry</i> , <b>2001</b> , 50, 873-83	7.9	294
20	Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. <i>Annual Review of Medicine</i> , <b>2001</b> , 52, 503-17	17.4	262
19	Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. <i>Canadian Journal of Psychiatry</i> , <b>2000</b> , 45, 241-6	4.8	62
18	Atypical antipsychotics: are some more atypical than others?. <i>Psychopharmacology</i> , <b>2000</b> , 148, 3-15	4.7	126
17	Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 514-20	11.9	844
16	A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. <i>Archives of General Psychiatry</i> , <b>2000</b> , 57, 553-9		370
15	Clinical and theoretical implications of 5-HT <sub>2</sub> and D <sub>2</sub> receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 286-93	11.9	448
14	Conventional versus novel antipsychotics: changing concepts and clinical implications. <i>Journal of Psychiatry and Neuroscience</i> , <b>1999</b> , 24, 431-41	4.5	23
13	D <sub>2</sub> and 5-HT <sub>2</sub> receptor effects of antipsychotics: bridging basic and clinical findings using PET. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60 Suppl 10, 15-9	4.6	20
12	Pharmacotherapy of first-episode schizophrenia. <i>British Journal of Psychiatry</i> , <b>1998</b> , 172, 66-70	5.4	53
11	Pharmacotherapy of first-episode schizophrenia. <i>The British Journal of Psychiatry Supplement</i> , <b>1998</b> , 172, 66-70		9
10	The relationship between D <sub>2</sub> receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. <i>Psychopharmacology</i> , <b>1997</b> , 131, 148-52	4.7	101
9	Depression in schizophrenia: a comparison of three measures. <i>Schizophrenia Research</i> , <b>1996</b> , 20, 205-9	3.6	87
8	Management of Acute Antipsychotic-Induced Extrapyramidal Syndromes. <i>CNS Drugs</i> , <b>1996</b> , 5, 21-35	6.7	11
7	Serotonin-dopamine interaction and its relevance to schizophrenia. <i>American Journal of Psychiatry</i> , <b>1996</b> , 153, 466-76	11.9	721
6	The D <sub>2</sub> dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. <i>Life Sciences</i> , <b>1995</b> , 57, PL103-7	6.8	150
5	Placebo response in refractory tardive akathisia. <i>Canadian Journal of Psychiatry</i> , <b>1993</b> , 38, 248-50	4.8	10
4	A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , <b>1993</b> , 13, 257-64	17.0	512

- |   |  |     |    |
|---|--|-----|----|
| 3 | The remitting atypical psychoses: clinical and nosologic considerations. <i>Canadian Journal of Psychiatry</i> , <b>1990</b> , 35, 36-40                   | 4.8 | 13 |
| 2 | Ethnocultural factors in resident supervision: black supervisor and white supervises. <i>American Journal of Psychotherapy</i> , <b>1989</b> , 43, 398-404 | 1.3 | 18 |
| 1 | Gas sniffing as a form of substance abuse. <i>Canadian Journal of Psychiatry</i> , <b>1984</b> , 29, 31-5  | 4.8 | 16 |